Oturkibart Biosimilar Monoclonal Antibody (IL-4Rα) for Research

Cat No.: GMP-Bios-INN-1320

Anti-IL4R/CD124 therapeutic antibody (Pre-made Oturkibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Oturkibart (development codes QX-005N/HDM3016) is a monoclonal antibody targeting IL-4 receptor alpha (IL4R). It is developed for inflammatory conditions. Further development details are under investigation.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1320-1mg 1mg 3090
GMP-Bios-INN-1320-10mg 10mg
GMP-Bios-INN-1320-100mg 100mg
GMP-Bios-INN-1320-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Oturkibart biosimilar, Whole mAb, Anti-IL4R/CD124 Antibody: Anti-IL-4RA/CD124/IL4R/Interleukin-4 receptor subunit alpha therapeutic antibody
INN Name Oturkibart
Target IL4R/CD124
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G4
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status TBC
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2025
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC